A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
Joint Authors
Okada, Yuki
Hitaka, Daisuke
Kido, Takahiro
Kanai, Yu
Konishi, Kumi
Doki, Kosuke
Katayama, Nobuko
Homma, Masato
Miyazono, Yayoi
Takada, Hidetoshi
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-26
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity.
In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy.
The infant, born at 29 weeks and 6 days of gestational age with a birth weight of 1664 g, had no congenital anomalies.
This case presents detailed information on the development of an infant with placental transfer of tamoxifen.
The infant has grown and developed normally throughout a 5-year follow-up period, but long-term vigilance continues.
American Psychological Association (APA)
Okada, Yuki& Hitaka, Daisuke& Kido, Takahiro& Kanai, Yu& Konishi, Kumi& Doki, Kosuke…[et al.]. 2020. A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen. Case Reports in Pediatrics،Vol. 2020, no. 2020, pp.1-4.
https://search.emarefa.net/detail/BIM-1150605
Modern Language Association (MLA)
Okada, Yuki…[et al.]. A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen. Case Reports in Pediatrics No. 2020 (2020), pp.1-4.
https://search.emarefa.net/detail/BIM-1150605
American Medical Association (AMA)
Okada, Yuki& Hitaka, Daisuke& Kido, Takahiro& Kanai, Yu& Konishi, Kumi& Doki, Kosuke…[et al.]. A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen. Case Reports in Pediatrics. 2020. Vol. 2020, no. 2020, pp.1-4.
https://search.emarefa.net/detail/BIM-1150605
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1150605